Terminated PHASE1 INTERVENTIONAL 4-arm NCT04989387

Study of INCA 0186 in Subjects With Advanced Solid Tumors

A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

Sponsor: Incyte Corporation

Conditions Advanced Solid Tumors Gastrointestinal (GI) Malignancies Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions INCA00186 INCB106385 Retifanlimab

Updated 20 times since 2021 Last updated: Aug 25, 2025 Started: Oct 4, 2021 Primary completion: Sep 19, 2024 Completion: Sep 19, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This was a strategic business decision. There were no safety concerns contributing to this decision.

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Advanced Solid Tumors trials with similar outcome

Browse all Advanced Solid Tumors trials

This PHASE1 trial investigates Advanced Solid Tumors and Gastrointestinal (GI) Malignancies and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 20 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Oct 2025 — Present [monthly]

Terminated PHASE1

Status: Completed → Terminated
Sep 2025 — Oct 2025 [monthly]

Completed PHASE1
Aug 2025 — Sep 2025 [monthly]

Completed PHASE1
Jun 2025 — Aug 2025 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Dec 2024 — Jun 2025 [monthly]

Active Not Recruiting PHASE1

▶ Show 15 earlier versions

Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Jan 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1
Aug 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Jan 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE1
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE1
May 2022 — Jun 2022 [monthly]

Recruiting PHASE1
Apr 2022 — May 2022 [monthly]

Recruiting PHASE1
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE1
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE1
Nov 2021 — Feb 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Brussels, Belgium , Cambridge, United Kingdom , Edegem, Belgium , Ghent, Belgium , Groningen, Netherlands , Hackensack, United States and 18 more locations